10.08.2016 – 07:15

Kuros Biosciences AG

EQS-Adhoc: Kuros appoints Philippe Saudan as Chief Development Officer

EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): Change of Personnel
Kuros appoints Philippe Saudan as Chief Development Officer

10.08.2016 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.


--------------------------------------------------------------------------------
Kuros appoints Philippe Saudan as Chief Development Officer

Schlieren (Zurich), Switzerland, August 10, 2016 - Kuros Biosciences announced
today that Dr. Philippe Saudan has been appointed Chief Development Officer and
member of the Executive Board with immediate effect. Dr. Saudan has spent the
last 16 years in the pharmaceutical industry and has held different management
roles in research and development (R&D). He has considerable experience in R&D
and international project management of multidisciplinary programs. In his last
position, he served as Chief Scientific Officer of Cytos Biotechnology, where he
worked at the interface between pre-clinical research, manufacturing and
development of several clinical projects. Since February 2016, Dr. Saudan has
been working as Head of Integration of Kuros Biosciences. In this position, he
has been closely involved in the different development programs in tissue repair
and regeneration. Dr. Saudan holds a PhD in biology
from the University of
Lausanne, Switzerland. 


For further information, please contact:
Kuros Biosciences Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46 
harry.welten@kuros.ch

About Kuros Biosciences Ltd

Kuros Biosciences Ltd is focused on the development of innovative products for
tissue repair and regeneration and is located in Schlieren (Zurich),
Switzerland. The Company is listed according to the International Financial
Reporting Standard on the SIX Swiss Exchange Ltd under the symbol KURN.
Information regarding Kuros is available atwww.kuros.ch.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider statements
that include the words "will" or "expect" or the negative of those words or
other similar words to be uncertain and forward-looking. Factors that may cause
actual results to differ materially from any future results expressed or implied
by any forward-looking statements include scientific, business, economic and
financial factors, Against the background of these uncertainties, readers should
not rely on forward-looking statements. The Company assumes no responsibility
for updating forward-looking statements or adapting them to future events or
developments.

 

End of ad hoc announcement
Additional features:


Document:http://n.eqs.com/c/fncls.ssp?u=AVTHLQIHUU
Document title: Kuros_CDO_160810

--------------------------------------------------------------------------------
10.08.2016 News transmitted by Tensid EQS AG. www.eqs.com

--------------------------------------------------------------------------------

Language: English

Company:  Kuros Biosciences AG

          Wagistrasse 25

          8952 Schlieren

          Switzerland

Phone:    +41 44 733 4747

Fax:      +41 44 733 4740

E-mail:    info@kuros.ch

Internet: www.kuros.ch

ISIN:     CH0011025217

Valor:    -

Listed:   Foreign Exchange(s) SIX


End of News EQS Group News Service
--------------------------------------------------------------------------------
490963  10.08.2016